ASH 2022 | Ultra-sensitive assessment of MRD in peripheral blood of patients with multiple myeloma using NGF
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, outlines data from a study that evaluated measurable residual disease (MRD) using next-generation flow (NGF) in the peripheral blood of patients with multiple myeloma enrolled in the GEM2014MAIN trial (NCT02406144). Overall, MRD assessment in peripheral blood using NGF was prognostic in patients under maintenance or observation. Moreover, adding an enrichment step to the method enabled MRD to be assessed down to 10-8 in peripheral blood, enhancing the identification of those at ultra-high risk of relapse. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Honoraria, Research Funding; Adaptive: Honoraria; GSK: Honoraria, Research Funding; EngMab: Research Funding; Sanofi: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding; Roche Glycart AG: Honoraria, Research Funding; Amgen: Honoraria; Gilead: Honoraria; Oncopeptides: Honoraria.
